This study was designed to determine the analgesic efficacy and tolerabtiity of parecoxib, cyclooxygenase-2 inhibitor, by comparing it with ketorolac and placebo in postoperative pain control after open prostatecto my. Sixty patients undergoing open prostatectomy were evaluated. The pa tients were divided into three equal groups. Group 1 received IV parecoxib 40mg, group II received IV ketorolac 30mg, and group III received IV pla cebo postoperatively every 6 hours for 24 hours. Postoperatively, all pa tients received intravenous morphine using patient controlled analgesia pump (PCA). The outcome measures included pain scores and morphine consumption in the first 24 hours postoperatively. Bleeding time was de termined immediately postoperatively and after 24 hours of the study drug administration. Parecoxib sodium 40mg reduced the total amount of morphine required over 24-hows by 36% also ketorolac 30rng reduced morphine consump tion by 33.5%, compared with placebo (P<0.001). Patients who received 40mg parecoxib sodium or 30mg ketorolac experienced significantly greater maximum pain relief compared with those in the placebo group (P <0.05). Patients who received 40mg parecoxib or 30 mg ketorolac discon tinued PCA with morphine earlier than patients received placebo and had significantly higher global evaluation ratings. Significant prolongation of bleeding time was observed in ketorolac group after 24 hours of its use |
